Search results for "ETC-1002"

showing 1 items of 1 documents

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct